大量基础和临床研究表明，动脉粥样硬化(atherosclerosis，AS)是一种慢性炎症性疾病，炎症反应 贯穿AS的各个阶段，但炎症在AS发生发展中的调节机制仍然尚未完全阐明。microRNA(miRNA)是 一类长度为21~25个核苷酸的小分子非编码RNA，在转录后水平通过降解或抑制靶标mRNA翻译来 调控靶基因的表达。已有研究证实，miRNA是参与心脑血管疾病的重要调控分子。MiR-155介导 的调节作用可广泛作用于内皮细胞、巨噬细胞、树突状细胞、血管平滑肌细胞、白细胞以及血小 板，通过对炎症相关基因的调控进而影响AS的发生发展。本文就miR-155对AS中所涉及到的不同 类型细胞的调节作用进行了综述。
Research progress in the roles of miR-155 in atherosclerosis
A great number of basic and clinical studies show that atherosclerosis is a chronic inflammatory disease and that inflammatory responses exist in all stages of development of atherosclerosis. Despite a lot of progress was made in recent years, the detailed mechanisms modulating the inflammation in atherosclerosis have not been fully elucidated. MicroRNAs (miRNAs) are a category of small non-coding RNAs with the length of about 21 to 25 nucleotides that regulate gene expression post-transcriptionally through degradation and translational repression of target messenger RNAs (mRNAs). Substantial evidence demonstrates that miRNAs play vital roles in cardiocerebrovascular diseases. miR-155-mediated regulation is extensively involved in endothelial cells, macrophages, dendritic cells, vascular smooth muscle cells, leukocytes and platelets. miR-155 can modulate the expression of inflammation-related genes which affect the development of atherogenesis. This paper reviewed the regulatory roles of miR-155 in various cell types involved in atherosclerosis.